• Join
  • Login
  • Contact

Search abstracts

Benralizumab effectiveness in patients with severe eosinophilic asthma.

  • At: Seville (Spain) (2022)
  • Type: Poster
  • Poster code: HPS-091
  • By: ARAGóN GRACIA, Irene (Hospital Universitario Marqués de Valdecilla, Spain)
  • Co-author(s): Mrs Irene Aragón Gracia, Hospital Pharmacist (Hospital Universitario Marqués de Valdecilla, Santander, Spain)
    Ms Lorenzo Perez-Periañez Orrillo, Hospital Pharmacist
    Mrs Julia Sanchez Gundin, Hospital Pharmacist
    Mrs Marta Valero Dominguez, Hospital Pharmacist
  • Abstract:

    Benralizumab is an anti-eosinophil, humanised afucosylated, monoclonal antibody (IgG1, kappa). It binds to the alpha subunit of the human interleukin-5 receptor (IL-5Rα) with high affinity and specificity.
    The IL-5Rα is specifically expressed on the surface of eosinophils and basophils. The absence of fucose in the Fc domain of..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses